Medications

Doctors divided over use of controversial new Alzheimer's drug

(HealthDay)—The controversial new Alzheimer's drug Aduhelm is creating something of a civil war in medicine, as health networks, hospitals, insurers and individual doctors weigh impending discussions with patients about ...

Alzheimer's disease & dementia

Depression, tau deposits seen in subset of middle-aged persons

Middle-aged people with depressive symptoms who carry a genetic variation called apolipoprotein (APOE) ε4 may be more at risk to develop tau protein accumulations in the brain's emotion- and memory-controlling regions, a ...

Alzheimer's disease & dementia

A new model of Alzheimer's progression

Alzheimer's disease is the most common form of dementia and is characterized by neurodegeneration in regions of the brain involved in memory and learning. Amyloid beta and tau are two toxic proteins that build up in disease ...

Alzheimer's disease & dementia

What happens in brain cells affected by Alzheimer's disease?

Affecting over 50 million people, Alzheimer's disease is the most common form of dementia and primarily occurs in people over the age of 65. The pathology of the disease in the brain is mainly characterized by two factors: ...

Medications

FDA defends approval of controversial Alzheimer's drug

The U.S. Food and Drug Administration has approved the first new drug to treat Alzheimer's disease in nearly two decades, in a controversial decision that left the agency defending its reputation and its science.

page 14 from 38